康惠制药: 康惠制药关于持股5%以上股东部分股权质押的公告

Summary of Key Points Core Viewpoint - The announcement details the pledge of shares by a major shareholder of Shaanxi Kanghui Pharmaceutical Co., Ltd., indicating a financial maneuver that does not significantly alter the company's equity structure or pose substantial repayment risks. Group 1: Shareholder Information - Shaanxi Kanghui Pharmaceutical's major shareholder, Yangzhou Chuangxiang Investment Partnership (Limited Partnership), holds 5,992,800 shares, representing 6% of the company's total equity [1]. - Chuangxiang Investment has pledged 1,997,600 shares, which accounts for 33.33% of its holdings and 2% of the total shares of the company [1]. Group 2: Pledge Details - The pledge registration date is set for July 2, 2025, with the maturity date on June 22, 2026 [1]. - The pledged shares do not involve significant asset restructuring or performance compensation guarantees [1]. Group 3: Financial Stability - Chuangxiang Investment is reported to have a good credit status and repayment capability, indicating no substantial repayment risk that could lead to significant changes in the company's equity structure [3].